Results 1 to 10 of about 5,939 (158)
Efficacy of Upadacitinib in Patients with Atopic Dermatitis of the Head and Neck Region [PDF]
Dermatology and TherapyIntroduction Head and neck atopic dermatitis (AD) is difficult to treat. We evaluated the efficacy of upadacitinib versus placebo in patients with head and neck AD in a post hoc analysis of Measure Up 1 (NCT03569293) and Measure Up 2 (NCT03607422 ...
Kilian Eyerich +10 more
doaj +2 more sources
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE study [PDF]
RMD OpenObjectives To assess the safety and efficacy of upadacitinib versus adalimumab through 7 years in the ongoing SELECT-COMPARE study.Methods Patients with rheumatoid arthritis (RA) and inadequate response to methotrexate (MTX) were randomised to placebo ...
Filip van den Bosch +13 more
doaj +2 more sources
Comparative Effectiveness of Upadacitinib vs. Other JAK Inhibitors in Patients With Rheumatoid Arthritis in a Global Real-World Setting [PDF]
Rheumatology and TherapyIntroduction This study aimed to compare the real-world effectiveness of upadacitinib vs. other Janus kinase inhibitors (JAKis) in patients with rheumatoid arthritis (RA). Methods Data were extracted from the Adelphi RA Disease Specific Programme™ (DSP),
Peter C. Taylor +7 more
doaj +2 more sources
Frontiers in ImmunologyIntroductionConventional rosacea treatments are not uniformly pervasive, and the adverse reactions can potentially constrain their utility. The clinical use of JAK1 inhibitors upadacitinib and abrocitinib in the treatment of refractory rosacea has rarely
Xian Jiang
exaly +3 more sources
Frontiers in ImmunologyBackgroundAtopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced by cytokines dependent on Janus kinases (JAKs).
Hidehisa Saeki +2 more
exaly +3 more sources
Treatment of Discoid Lupus Erythematosus with Upadacitinib: A Case Report
Clinical, Cosmetic and Investigational Dermatology, 2023 Wenting Hu, Si Zhang, Cuihong Lian Department of Dermatology, Shenzhen Second People’s Hospital, Shenzhen, Guangdong, People’s Republic of ChinaCorrespondence: Cuihong Lian, Department of Dermatology, Shenzhen Second People’s Hospital, No.
exaly +2 more sources
Predictive factors for responders to upadacitinib treatment in patients with atopic dermatitis
Journal of Dermatological TreatmentBackground Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors for high responders to upadacitinib have not been established in real-world clinical practice.Objectives To identify ...
Hidehisa Saeki +2 more
exaly +3 more sources
Upadacitinib in refractory ulcerative colitis patients with high thromboembolic risk: two case reports [PDF]
Frontiers in ImmunologyUpadacitinib is a novel selective Janus kinase (JAK) inhibitor approved for adults with ulcerative colitis (UC). While caution is advised when considering upadacitinib as a treatment option for patients with an increased risk of thrombosis.
Rui Mo +3 more
doaj +2 more sources
Heliyon, 2023 Background: The sparsity of head-to-head trials for medications used as in atopic dermatitis (AD) treatment makes therapy options difficult. Objective: To better compare the efficacy and safety of abrocitinib and upadacitinib with dupilumab in patients ...
Qin Gao, Yanxia Zhao, Junling Zhang
doaj +1 more source
Dermatology and Therapy, 2023 Introduction Upadacitinib, an oral selective Janus kinase (JAK) inhibitor, is used to treat moderate-to-severe atopic dermatitis (AD). Acne is the most common treatment-emergent adverse event in patients with AD treated with upadacitinib.
Nobukazu Hayashi +6 more
doaj +1 more source